Life Sciences Archive » May, 2016

Life Sciences - May, 2016

332 articles

• FDA Asks Teva For More Info On New Huntington's Drug
• Doctors Denied Early Win In Botox Action Against Allergan
• Pharma Co. Lawsuit Over FDA Threats Premature, Judge Says
• Attorney Web Bios: The Good, The Bad And The Ugly
• DC Circ. Revives Suit Over $325M Czech Arbitration Award
• Valeant Faces RICO Suit In 'Secret' Pharmacy Network Row
• Homeopathics Buyers Can't Change Trial Terms, Boiron Says
• Robbins Geller Will Lead Valeant Securities Fraud Suit
• FDA Warning Wire: Horizon Air, Spiders, Falsified Data
• Deals Rumor Mill: Carmila, Valeant, Bank of America
• Sun Pharma Unit Supoenaed In DOJ Generics Antitrust Probe
• Walgreens Dragged Into Theranos' Faulty Blood Tests Fight
• SV Life Sciences Raises $273.5M For Planned $400M Fund
• Wash. Medicaid Ordered To Cover Expensive Hep C Drugs
• Supreme Court Won't Hear Cubicin Patent Appeal
• Cooley, Kirkland Lead $1.5B Jazz Pharma Deal For Celator
• FDA And Digital Health: Time For A Cultural Exchange
• Neovasc Ducks Mass. Law Claim In Medical Device IP Suit
• 5 Signs You'll Never Excel In BigLaw
• Gibson Dunn DQ Shows Danger Of Handling Privileged Emails
• Chelsea Therapeutics Settles Investor Class Action For $5.5M
• Merrill Lynch, Citi Hit In Class Action Over Cancer Co. IPO
• Lipitor Retailers Push 3rd Circ. To Revive Pay-For-Delay Claims
• Abbott Pushes To Exclude Depakote Testimony On Eve Of Trial
• Behind The Curtain: Technical Advisers In Complex Cases
• Medical Device Co. Says IP Suit Triggers Defamation Policy
• FDA Delays Approval Of AstraZeneca Unit's Potassium Drug
• Takeaways From Chelsea Therapeutics Post-Closing Action
• Driven By Abstraction: Flaws In USPTO, Court 101 Analyses
• GOP Reps Chide HHS On Off-Label Marketing, Urge Changes
• Bayer Tops Pharma Reputation Report, Pfizer At Bottom
• Another Customer Hits Theranos With Blood Test Rip-Off Suit
• JPML Skeptical Of Consolidating Heart Med Suits
• J&J Seeks To Pause Hip Implant Trials After $502M Verdict
• Quinn Emanuel's New Zurich Office To Focus On Disputes
• KaloBios Seeks To Award Board Members For Saving Business
• FDA OKs Buprenorphine Implant To Treat Opioid Addiction
• Pols Wants Answers On Colombian Drug Licensing Policy
• FDA Inaction On Shellfish Petition Dangerous, Suit Alleges
• How To Prepare Your Employees For Litigation Discovery
• 5 Tips For Negotiating And Drafting Joint E-Discovery Plans
• Genetically Modifying Mosquitoes Could Stem Spread Of Zika
• Theranos' Faulty Blood Tests Ripped Off Patients, Suit Says
• Patent Board Kills 3 Ariosa Re-Exams Of Illumina Patent
• Europe Floats Proposal On Drug Cooperation In TTIP
• Class Attys Want OK Of $1B Deal To End Vioxx Marketing Row
• Sanofi Tries To Boot Medivation Board In $9.3B Hostile Bid
• Sanofi Wants Jury Verdict Axed In Amgen Drug Patent Row
• Fed. Circ. Won't Rehear IP Row Over Container Patent
• AstraZeneca Says Del. Order Ends Dr. Reddy's NJ Nexium Suit
• Senju Settles Out Of Apotex's Pinkeye Meds Antitrust Suit
• Pfizer Beats FCA Suit Over Geodon Marketing
• Costco Drops Antitrust Suit Against J&J Over Contact Lenses
• Generic Drugmaker Wins Review Of UCB's Vimpat Patent
• Calif., Wash. Hit J&J With State Lawsuits Over Pelvic Mesh
• Merck Investors Fight For American Pipe Tolling At 3rd Circ.
• PTAB Won't Review Suboxone IP After Teva Misses Deadline
• Bayer Rips Probiotic Class's Use Of 'Rhetoric, Not Evidence'
• FDA Warning Wire: Suspect Data, Bakery Bugs, Faulty Tests
• Fenwick To Launch NYC Office With West Coast Partners
• Medtronic Can't Shake FCA Kickback Claims
• Green Lights Ahead For Medical Pot Legal Work In Pa.
• Stock Tipper Blasts SEC's Newman Stance In 3rd Circ.
• OrbiMed Nets $307M For Israel Health Care Fund
• 1st Circ. Keeps Alive One Claim In Genzyme Drug Dispute
• An FCA Update As We Await High Court's Escobar Decision
• Monsanto Snubs Bayer's $62B Buyout Offer
• Calif. Asbestos Case Opens Door For Shaky Expert Opinions
• Panama Papers: Reminders About Law Firm Cybersecurity
• High Court Urged To Deny Review Of Nixed DNA-Test Patent
• Bayer's $62B Monsanto Bid Would Break Industry Record
• Reed Smith In Houston Snags Antitrust Pro From K&L Gates
• Medtronic, Ex-Sales Rep Settle Alleged Retaliation Suit
• Deals Rumor Mill: Anthem, Teva, SF Holdings
• GOP Unveils New Tactics To Reform ACA Programs
• Oil Explorer, Biotech Junk IPOs Amid Bumpy Market
• Reed Smith Widow Says Expert Was Cleared In Patient Suicide
• Ex-Stryker Salesman Appeals Sanctions To 6th Circ.
• Kyle Bass Convinces PTAB To Review Citius Drug Patent
• 4th Circ. Won't Rehear Bayer's Trademark Case Over Flanax
• Bayer Confirms $62B Offer For Monsanto
• In Congress: Defense Bill, TSCA Reform, Authority Over DC
• Jailed Stock Scheme Atty Says Gov't Misconduct Tainted Case
• Chelsea Shareholders Lose Suit Over Drugmaker's Sale
• Health Hires: K&L Gates, Norton Rose Get Health, IP Attys
• Long Beach Hits Monsanto, Pfizer Unit With Enviro Suit
• Bayer-Monsanto Deal Would Be Tough Sell For Regulators
• Ex-Gilead Recruiter's Atty Defends Use Of Settlement Details
• Actos Buyers Press 2nd Circ. To Revive Antitrust Claims
• Generic-Drug Price-Fixing Suits Belong In Pa., JPML Told
• Supplement Co. Dials Back Promos To End FTC False Ad Suit
• OPINION: Sotomayor's Solution To Pro Bono Is Incomplete
• Creating Barclay Damon: Lessons From A Law Firm Merger
• Tyco Says $60M Drug Heist Trial Win Should Stand
• Myriad Genetics Hit With HIPAA Complaint Over Gene Data
• $13B Salix-Valeant Merger Row Tossed In Del. Chancery
• Neovasc Hit With $70M Verdict In IP, Trade Secrets Trial
• Reflecting On The 20th Anniversary Of BMW V. Gore
• Boutique Tabet DiVito Snags Patent Atty From Katten Muchin
• Fed. Circ. Affirms Denial Of Fees For Dropped Patent Suit
• Probiotic Maker Denies Lying About Sigma, VSL Products
• Fed. Circ. Urged Not To Rehear Generics Jurisdiction Ruling
• Eisai Asks 3rd Circ. To Rehear Lovenox Antitrust Suit
• Deals Rumor Mill: Onex, Sensus USA, Yum Brands
• Bellwether Trials In Doubt After Another Zimmer MDL Setback
• USPTO To Evaluate Eligibility, Obviousness Rejections
• Nexium Pay-For-Delay Trial Needs Redo, Buyers Tell 1st Circ.
• Actavis, Others Can't Yet Market Generic Nucynta, Judge Says
• Attys Scratch Heads As FDA Punts Generic-Label Rule To 2017
• Corporate Counsel: Consumer Becomes Provider (The Sequel)
• Theranos Admits More Than 10K Test Results Were Erroneous
• Judge Says Turing Concedes Liability In Impax AIDS Drug Row
• Still Some Gaps In FDA 3-D Printed Medical Device Guidance
• Judge Posner Slams Courts' Use Of 'Stale, Opaque' Jargon
• Tenn. Health Group Says Clinic Wasn't Agent In Meningitis MDL
• Supplement Co. Asks 9th Circ. For Rehearing In False Ad Suit
• Biopharm Co. To Repay Lender $4M In Ch. 11 Collateral Row
• Settlement Floated In Investor Suit Over Cornerstone Buyout
• House OKs $622M Zika Bill That Dems Say Won't Stop Virus
• Nexium Buyers Defend New Trial Bid In Pay-For-Delay Suit
• Takeda's Suit Targeting Rival Gout Drug Is Dismissed
• B. Braun Admits Tainted Syringe Sales In $7.8M Settlement
• Deals Rumor Mill: Monsanto, Goldman, Hotel Lotte
• Medtronic Drops $350M On Smith & Nephew Gynecology Unit
• No New Trial For Abbott Whistleblower In $219M Stent Row
• Janssen Diabetes Drugs Linked To Amputations, FDA Says
• 5th Circ. Axes Testimony Behind Light Therapy Defect Verdict
• Ex-Warner Chilcott Exec Wants Recordings Barred From Trial
• High Court Is Lost In The Woods With The Laws Of Nature
• Jury Rules Bayer Unit Didn't Copy Foot Care Rival's Marks
• Uptick In FCPA Enforcement Suggests 2015 Drop Was Outlier
• Gilead Fights $50M Bonus Demand After EU Cancer Drug OK
• FDA Warning Wire: Issues At Plant Linked To Listeria
• FDA Rebuked For Blocking Cancer Patient's Treatment
• CVS Tells 1st Circ. Disclaimer Sinks Vitamin E Label Fight
• Coherus Scores Review Of An AbbVie Humira Patent
• Dr. Scholl's Foot Care Logo Dispute Now Up To Jury
• Novartis Splits Pharma Biz In Two, Parts With Drug Exec
• Deals Rumor Mill: Asahi Group, Investcorp, Valeant
• Baxter Infusion Pump Patents Survive Alice Challenge
• 2nd Circ. Affirms Dismissal Of Lipitor Off-Label Marketing Suit
• GSK, Teva Press High Court To Hear Lamictal Case
• OPINION: Stop 'Vigorously Defending' Your Clients
• Vague Claims, Immunity Doom Painkiller Data Suit, UC Says
• The Myth Of 'Price Disconnects' In US Pharma Markets
• Supplement Co. Seeks End To 'Gamesmanship' In Label Suit
• 2nd Circ. Urged To Adopt Octane Fitness In Trademark Cases
• Thermo Fisher To Pay $35M In Enzo DNA Patent Row
• 2nd Circ. Tosses Apotex's False Ad Row Over MS Drug
• IMS Health Investor Seeks To Halt $9B Quintiles Merger
• Valeant Expands Drug Discount Program After Price Increases
• Fed. Circ. Rules Glenmark Infringed Bayer's Finacea Patent
• PE-Backed Cos., Biotech Prime 3 IPOs Totaling $439M
• Cubist Asks High Court To Review Nixing Of Cubicin Patents
• Wachtell Guides Pfizer's $5.2B Anacor Deal
• A Look At USPTO's New Patent-Eligibility Examples
• The Top 100 Firms For Minority Attorneys
• The Top 50 Firms For Minority Equity Partners
• White & Case Outpacing Peers In Diversity
• US Law Firms Fail To Move Needle On Racial Diversity
• The 5 Ways BigLaw Is Failing Minorities
• Split 6th Circ. Clears Abbott In FCA Suit Alleging Bribe
• Lab's Insurer Ducks Coverage For Suit Over Dead Horses
• Jazz Makes Deal In Xyrem IP Fight With Ranbaxy, Sun, Ohm
• City Sues Allergan, Mylan, Others Over Generic Price Hikes
• Fed. Circ. Says Merck Patent Nixed By On-Sale Bar
• J&J Unit Settles Its Patent Suit Over Glucose Testing Strip
• 6 Firms Steer 4 IPOs Totaling $937M Led By Blank Check Deal
• Amgen Lobs Patent Suit At Sandoz's Neulasta Biosimilar
• Pfizer Drugs Can't Be Used For Executions Anymore
• House Passes Comprehensive Anti-Opioid Abuse Bill
• Deals Rumor Mill: Teva, ConvaTec, Abraaj
• Sanofi Says Evidence Doesn't Justify Verdict In Patent Suit
• AIDS Group Agrees To Drop 2 Cos. From Drug Antitrust Row
• Taxation With Representation: Weil, Skadden, Morrison Cohen
• Cravath Guides Mylan In Up To $1B Deal For Pharma Biz
• False Ad Row Over Homeopathic Label Moves Closer To Trial
• 23andMe Says Insurer Must Cover Suit Over Test Accuracy
• 5 Ways To Avoid Obviousness-Type Double Patenting
• Half Of Workstation's Patent Claims Obvious, PTAB Rules
• Fed. Circ. OKs Use Of Local Patent Rule To Nix Stryker Case
• KaloBios Must Make Decision On Drug Trials, Hospital Says
• US Urges High Court To Review Fed. Circ. Life Tech Ruling
• 23andMe Can't Arbitrate False Ad Suits, 9th Circ. Told
• FDA Orders Stronger Warning Labels For Antibiotic Class
• Fresenius Gets PTAB To Deal Another Blow On Cubicin Patents
• Deals Rumor Mill: SingTel, Bayer, Bosch
• Fried Frank Adds Ex-Reed Smith Atty To M&A Practice
• Sanofi Wins Temporary Reprieve From Kickbacks Action
• Norton Rose Adds Gowling Corporate Partner In Toronto
• Records To Be Unsealed From Ky. OxyContin Suit
• Flintstones Gummy Buyers Seek Cert. In Suit Against Bayer
• Food Co. Sues Commerce For Bungled Customs Instructions
• Aegerion To Admit Guilt, Pay $40M Over Drug Marketing
• Corporate Counsel: Consumer Becomes Provider
• New PTAB Chief Judge Hailed For Patent Prowess
• Genentech Asks For Sanctions In Kadcyla Patent Suit
• Merck, Genentech Sold Unapproved Drugs, FCA Suit Says
• House Passes New Hurdles For Opioid Drug Approvals At FDA
• FDA Eyes New Fees For Makers Of Over-The-Counter Drugs
• FDA Warns Antipsychotic Drug Can Cause Severe Skin Rash
• Genzyme, Sanofi's Cancer Drug Patent Ruled Valid
• $54M Tobacco IPO Misses Mark, Biotech Curtails Debut
• Colo. Pot Dispensary Fights IRS Over Uprooted Deductions
• Supplement Co. Says Rival's Protein Quality Claims Are False
• Pa. Appeals Court Upholds $3M Verdict In J&J Topamax Case
• What Do The Highest-Paid Lawyers Make An Hour?
• Medtronic Patent Exec Named PTAB Chief Judge
• Allergan Faces Hydrocortisone Antitrust Probe In UK
• USPTO Memo Leaves Eligibility Questions Unanswered
• Recovery Claims: A New Source Of University Funding
• Dr. Scholl's Copied Rival Foot Care Co.'s Logo, Jury Told
• J&J, Merck, Endo Probed Over Pharmacy Benefit Managers
• Express Scripts Looks To Deep-Six Pharmacy Antitrust Claims
• E-Cig Co. Nicopure Sues FDA To Block New Oversight
• Loestrin Buyers Allege Product-Hopping By Warner Chilcott
• Deals Rumor Mill: ABF, Telecom Italia, Pershing Square
• PharMerica Says Public Disclosure Testimony Sinks FCA Suit
• House Passes Five Bills To Curb Opioid Abuse
• Fed. Circ. Backs Medtronic Win In Heart Valve Patent Review
• $2.5M Philly Risperdal Verdict Against J&J Will Stay Put
• FDA Warning Wire: 'Deep Concerns' Prompt Rare Recall Action
• Hospitals Can't Blame Gov't In Meningitis MDL, Judge Told
• Feds Seek $3.7M In Unpaid Fees From Fla. Tobacco Importer
• 'Flanax' Ruling Driven By 'Ethical Outrage,' Drug Co. Says
• 4 Steps To Effective FCPA Acquisition Due Diligence
• Endo, Impax Can't Trim Opana Pay-For-Delay MDL, Class Says
• Genentech Facing Class Action Over Cancer Drug Skimping
• K&L Gates Adds IP Partner From DLA Piper In Australia
• Colo.-Based Marijuana Biz Law Firm Expands Into Fla.
• Sex Supplement Buyer Pushes For Cert. In False Ad Suit
• Pfizer Ducks State Law Label Claims In Lipitor MDL
• Loeb OK'd To Drop Client Suing Ex-IP Atty Over Secrets
• Fed. Circ. Stresses PTAB Rules In Affirming DNA Patent Ruling
• How To Turn Nonbillable Work Into Big Bucks
• Tenn. Hospitals Want Discovery Stays Lifted In Meningitis MDL
• Fed. Circ. Affirms Tossing Of Monitoring Patent Under Alice
• Docs, Drugmakers Call Medicare Pay Experiment Unlawful
• Vitamin Health Not Covered For False Ad Suit, Court Says
• Only Public Sales Trigger AIA On-Sale Bar, USPTO Says
• PharMerica Off The Hook For Successor Liability In FCA Suit
• Health Care Funds Push For Class Cert. In Celexa Drug MDL
• Biotech Cos. Face Pressure To Disclose
• Deals Rumor Mill: Medivation, Triton, Cinven
• Gilead Says Secret Info Being Used By Atty In Harassment Suit
• Abbott Whistleblower Seeks New Trial In $219M Stent Row
• Biolitec Can't Re-Litigate $70M Contempt Order, 1st Circ. Says
• Boston Scientific, Cook Medical Face Vein-Filter Suits
• USPTO Patent Guidelines Give Hope To Life Sciences Cos.
• Investors Say Greatbatch Lied About Stock Incentive Plan
• Del. Judge OKs KaloBios Ch. 11 Disclosure, Investor Pact
• Endo Hits Impax With $100M Suit Over Painkiller IP Agreement
• Fed. Circ. Backs Acacia Unit's PTAB Loss Over Stent Patent
• SEC Says Water Purifier CEO May Have Clean Hands After All
• Health Hires: Wilson Sonsini Gets Bump In M&A, Cooley In IP
• GNC Says Pa. Investor Suit Fatally Relies On Ore. AG Action
• BTG Buying US Oncology Products Maker In $110M Deal
• GSK Rips New Trial Bid From Alleged Paxil Birth Defect Victim
• Deals Rumor Mill: Teva, Colony Capital, Riverstone Holdings
• Intercept To Pay $55M To End Investors' Stock-Drop MDL
• Takeda Says 2nd Circ. Shouldn't Revive Actos Antitrust Row
• The Fastest Rocket Docket For The 8th Straight Year
• Intellia's $108M IPO Leads Pair Of Biotech Floats
• 3rd Circ. Urged To Revive Label Suit Against Novartis
• Medtronic Says Guidant Could Be Liable For Patent Row Fees
• Insurance Coverage Implications Of The J&J Talc Verdicts
• Herbalife Says FTC Talks 'Advanced,' $200M Deal Possible
• USPTO Calls For Clearer Alice Rejections, Aiding Applicants
• Daiichi Sankyo Wins $385M From Ranbaxy's Ex-Owners
• Shkreli Associate Says He Was Cut Out Of $8M KaloBios Pact
• Quest, Contractor Reach Settlement In $90M Debt Dispute
• Actavis Continues Fight For Generic Lialda At Fed. Circ.
• House Democrats Push For $600M To Fight Opioid Abuse
• Amended Sobriety Test Patent Still Nothing New, PTAB Says
• FTC Approves $2.2B Hikma Deal, Pending Divestitures
• Insurer Must Cover Hernia Mesh Trade Secret Row, Court Told
• Express Scripts Hid Risk of Losing Major Client, Investors Say
• High Court Likely To Look At Scope Of US Patent Law Abroad
• Hospira To Fed. Circ.: Don't Alter On-Sale Rule For Patents
• Biomedical Orthopedic Implant Patent Survives AIA Review
• 6 Ways Lawyers Can Enhance Cross-Office Communication
• Peregrine Knew Cancer Drug Trials Were Bunk, 9th Circ. Told
• 8th Circ. Boosts TCPA Class Cert. Bids In Medtox Ruling
• Pfizer Cools To Tax Inversion After Nixed Allergan Deal
• Bayer Wants All Mirena IUD Cases Tossed For Lack Of Experts
• Del. Action Against CytRx Stayed Pending Calif. Court Deals
• Lilly, Canada Clash On NAFTA Filings In $388M Patent Fight
• Fed. Circ. Skeptical Becton Dickinson Patent Survives Alice
• J&J's Talcum Trial Losses Create Litigation Powder Keg
• Fed. Circ. Won't Rehear Ruling That Axed 4 OxyContin Patents
• Deals Rumor Mill: Pfizer, Hellman & Friedman, Carlyle
• Sonova Inks $955M Deal For Hearing Aid Retailer AudioNova
• Colgate Faces New False Ad Suit Over Tooth Whitening Claims
• Fed. Circ. Urged To Rehear Jurisdiction Ruling On Generics
• 3rd Circ. Rejects Lovenox Antitrust Suit Against Sanofi
• Fed. Circ. Could Ease On-Sale Bar Threat To Pharma Patents
• What Is Your Squirm Factor?
• Scalia's Vacancy Shifts High Court On Class Actions
• Valeant — A Case Study In Rotten Culture And Business Ethics
• Paul Weiss Snags Dechert Partner, Ex-Philip Morris GC
• Supplement Sellers Pay FTC $9.2M For Deceiving Consumers
• Supplement Buyers Fight To Keep Class Cert. In False Ad Suit
• Rulings Clear Up Controversy Over Fla. Medical Pot License
• FCA Penalties Set To Double, Raising Fears Of Excess Fines
• Big-Ticket Pharma Plays Help 2 Law Firms Dominate April M&A
• FDA Warning Wire: Cancer Treatment Co. Again Under Fire
• WilmerHale Lures 2 Corporate Attys From White & Case
• Mylan Wins PTAB Review Of Diabetes Drug In Rare Rehearing
• Acacia Asks Fed. Circ. To Nix Delay Defense In Stent IP Row
• 8th Circ. Revives Medtox Junk Fax Suit
• 2 Biotechs Set Terms On IPOs Totaling $108M
• FDA Warns Abilify Tied To 'Uncontrollable Urges' For Sex, Food
• KaloBios Investor Settlement Hints At Kaye Scholer Suit
• VA Now Open To Non-Trade Agreements Act Compliant Drugs
• Pharma Bad Boy Shkreli May Face Additional Criminal Charges
• Eli Lilly Ducks Suit Over Zyprexa Side Effects
• Allergan, Others Hit With Another Drug Price-Fixing Suit
• Quintiles, IMS Health To Join In $8.9B Merger Of Equals
• Depomed Tells Fed. Circ. AIA Reviews Are Unconstitutional
• Heart Drug IP Relies On Obvious Aspirin Combo, PTAB Told
• Amneal Fights To Maintain Claims In Suboxone MDL
• KaloBios Reaches Deal To End Fight Over $8M Investment
• Lamictal Buyers Ask High Court Not To Take Antitrust Case
• Endo Fights In Fed. Circ. To Keep Opana Painkiller Patents
• Impax Sues Ex-Shkreli Co. For $20M In Daraprim Dispute
• J&J Hit With $55M Verdict In Ovarian Cancer Trial
• TTAB Refuses Mucinex 'Mini Melts' TMs
• Diet Pill Co., Snooki Won't Get 2nd Circ. Input In False Ad Suit
• Judge Slams 'Outrageous' Delay In Settlement Malpractice Row
• Kohlberg Nabs Majority Stake In Spinal Medical Device Maker
• Pioneer Drug For Parkinson's Psychosis Wins FDA Approval
• Class Attys In Vioxx Case Ask For Approval Of $1B Deal